Darzalex Faspro

Active Ingredient(s): Daratumumab + Hyaluronidase-fihj
FDA Approved: * May 1, 2020
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Darzalex Faspro Overview

Daratumumab/hyaluronidase, sold under the brand name Darzalex Faspro, is a fixed-dose combination medication for the treatment of adults with newly diagnosed or relapsed/refractory multiple myeloma.[2][1] It is a combination of daratumumab and hyaluronidase.[1] It is administered via subcutaneous injection.[1] The most common adverse reaction using daratumumab/hyaluronidase as monotherapy is upper respiratory tracts infection.&am...

Read more Darzalex Faspro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daratumumab/hyaluronidase

Recent Darzalex Faspro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Daratumumab + Hyaluronidase-fihj
  • Injection: 120mg + 2000units/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Darzalex Faspro: (1 result)

Sorted by National Drug Code
  • 57894-503 Darzalex Faspro Subcutaneous Injection by Janssen Biotech, Inc.

Drugs with one or more similar ingredients: (3 results)